Prostate Cancer - Results from #20

Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. December 30, 2024

Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer. December 30, 2024

Time to Refine Prostate Cancer Epidemiology: Defining New Endpoints for Effective Screening and Causal Epidemiological Studies. December 27, 2024

Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data. December 27, 2024

High Detection Rates for Prostate-specific Membrane Antigen-avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography. December 27, 2024

Total Prostate-Specific Antigen (PSA) Testing in Capillary Samples: Proof-of-Principle and Feasibility Study for Home Self-Testing for Prostate Cancer. December 27, 2024

Automatic MRI-TRUS Fusion Technique for Transperineal Biopsy Guidance: From Preoperative Planning to Intraoperative Navigation. December 27, 2024

Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021). December 27, 2024

Increasing Life Expectancy in Patients with Genitourinary Malignancies: Impact of Treatment Burden on Disease Management and Quality of Life. December 26, 2024

Daily life mobility detects frailty, falls, and functioning in older prostate cancer survivors treated with androgen deprivation therapy. December 26, 2024

Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI. December 26, 2024

Long-Term Oncological Outcomes of Active Surveillance for Low-Risk Prostate Cancer Diagnosed During the MRI Era. December 26, 2024

Occupational exposures of firefighting and prostate cancer risk in the Norwegian Fire Departments Cohort. December 26, 2024

Mature effectiveness and toxicity outcomes associated with three treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. December 26, 2024

Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer. December 25, 2024

CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer. December 25, 2024

Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer. December 25, 2024

An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer. December 25, 2024

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617. December 24, 2024

Partial or Focal Brachytherapy for Prostate Cancer: A Systematic Review and Meta-Analysis. December 24, 2024

Page 2 of 1449